Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 12Sarcoma 10Plasma cell 7Lymphoid 7Genitourinary 6CNS 5Myeloid 4Thoracic 3Dermatologic 3Other solid neoplasm 2Gastrointestinal 2Classical hematology 2Breast 2Other neoplasm 1Head & Neck 1

Conditions

Waldenstrom Macroglobulinemia 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hodgkin Disease 1Hematologic Neoplasms 1Graft vs Host Disease 1Anemia, Refractory, with Excess of Blasts 1Anemia, Aplastic 1

Interventions

fludarabine phosphate 12Whole-Body Irradiation 11Peripheral Blood Stem Cell Transplantation 11Cyclophosphamide 11Mycophenolic Acid 9fludarabine 7Cyclosporine 6Busulfan 6Tacrolimus 4Melphalan 4Filgrastim 4Cytarabine 4Cord Blood Stem Cell Transplantation 4Antilymphocyte Serum 4eltrombopag 3Flow Cytometry 3Cytogenetic Analysis 3Cyclosporins 3Alemtuzumab 3AP 1903 reagent 3romiplostim 2Transplantation 2Topotecan 2Thiotepa 2Sirolimus 2SRA737 2Radiotherapy 2Gene Expression Profiling 2Etoposide 2Decitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Sirolimus × Classical hematology × Clear all
NCT03192397 2026-04-14

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Roswell Park Cancer Institute

Phase 1/2 Active not recruiting
35 enrolled 19 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Graft vs Host Disease, Hodgkin Disease, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT01203722 2026-02-19

Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
87 enrolled 24 charts
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Lymphoma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡